Literature DB >> 15294881

Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Zhi You Fang1, Johannes B Prins, Thomas H Marwick.   

Abstract

The presence of a diabetic cardiomyopathy, independent of hypertension and coronary artery disease, is still controversial. This systematic review seeks to evaluate the evidence for the existence of this condition, to clarify the possible mechanisms responsible, and to consider possible therapeutic implications. The existence of a diabetic cardiomyopathy is supported by epidemiological findings showing the association of diabetes with heart failure; clinical studies confirming the association of diabetes with left ventricular dysfunction independent of hypertension, coronary artery disease, and other heart disease; and experimental evidence of myocardial structural and functional changes. The most important mechanisms of diabetic cardiomyopathy are metabolic disturbances (depletion of glucose transporter 4, increased free fatty acids, carnitine deficiency, changes in calcium homeostasis), myocardial fibrosis (association with increases in angiotensin II, IGF-I, and inflammatory cytokines), small vessel disease (microangiopathy, impaired coronary flow reserve, and endothelial dysfunction), cardiac autonomic neuropathy (denervation and alterations in myocardial catecholamine levels), and insulin resistance (hyperinsulinemia and reduced insulin sensitivity). This review presents evidence that diabetes is associated with a cardiomyopathy, independent of comorbid conditions, and that metabolic disturbances, myocardial fibrosis, small vessel disease, cardiac autonomic neuropathy, and insulin resistance may all contribute to the development of diabetic heart disease.

Entities:  

Mesh:

Year:  2004        PMID: 15294881     DOI: 10.1210/er.2003-0012

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  286 in total

Review 1.  Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease.

Authors:  Guanghong Jia; Adam Whaley-Connell; James R Sowers
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.

Authors:  Pavan K Battiprolu; Thomas G Gillette; Zhao V Wang; Sergio Lavandero; Joseph A Hill
Journal:  Drug Discov Today Dis Mech       Date:  2010

Review 3.  What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes.

Authors:  Rodica Pop-Busui
Journal:  J Cardiovasc Transl Res       Date:  2012-05-30       Impact factor: 4.132

4.  Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes.

Authors:  Véronique A Lacombe; Serge Viatchenko-Karpinski; Dmitry Terentyev; Arun Sridhar; Sitaramesh Emani; John D Bonagura; David S Feldman; Sandor Györke; Cynthia A Carnes
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-08-29       Impact factor: 3.619

5.  Left ventricular mechanical dyssynchrony assessment in long-standing type II diabetes mellitus patients with normal gated SPECT-MPI.

Authors:  Dharmender Malik; Bhagwant Mittal; Ashwani Sood; Madan Parmar; Gurvinder Kaur; Ajay Bahl
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

Review 6.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Role of cardiac MRI in diabetes.

Authors:  Ravi V Shah; Siddique A Abbasi; Raymond Y Kwong
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

8.  Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells).

Authors:  C Alfarano; L Sartiani; C Nediani; E Mannucci; A Mugelli; E Cerbai; L Raimondi
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 9.  Glycemic control and treatment patterns in patients with heart failure.

Authors:  W H Wilson Tang
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

10.  The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

Authors:  T Radovits; T Bömicke; G Kökény; R Arif; S Loganathan; K Kécsán; S Korkmaz; E Barnucz; P Sandner; M Karck; G Szabó
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.